1-2 of 2
Theodora W. Salcedo, PhD DABT
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Novel Semi-Mechanistic Model Leveraging Preclinical and Clinical Data to Inform the Recommended Phase 2 Dose (RP2D) Selection for Epcoritamab (DuoBody CD3xCD20)

Tommy Li, PhD, Ida H Hiemstra, PhD, Christopher Chiu, PhD, Roberto S Oliveri, MD PhD, Dena DeMarco, Theodora W. Salcedo, PhD DABT, Frederikke Lihme Egerod, PhD, Manish Gupta, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 35–36.
https://doi.org/10.1182/blood-2020-139457
Published: 2020
Journal Articles

Duobody-CD3xCD20 Shows Unique and Potent Preclinical Anti-Tumor Activity in Vitro and In Vivo , and Is Being Evaluated Clinically in Patients with B-Cell Malignancies

Ida H. Hiemstra, PhD, Patrick J. Engelberts, BS, Bart de Jong, BS, Danita H Schuurhuis, PhD, Theodora W. Salcedo, PhD DABT, Sandra Verploegen, PhD, Marten van der Zee, PhD, Arnout F. Gerritsen, PhD, Nedjad Losic, PhD, Sjeng Horbach, PhD, Roberto Oliveri, MD PhD, Jeroen J. Lammerts van Bueren, PhD, Pernille Autzen Usher, PhD, Janine Schuurman, PhD, Paul W. H. I. Parren, PhD, Esther C. W. Breij, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1664.
https://doi.org/10.1182/blood-2018-99-115957
Published: 2018